Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Open-Label, Single-Arm Study With an Initial Safety Run-In and Dose Expansion of ICG318 (BCMA-CD19-IL-15/IL15sushi cCAR T) in Participants With Refractory Systemic Lupus Erythematosus, With or Without Lupus Nephritis

NCT07328581 is registered in ClinicalTrials.gov with iCell Gene Therapeutics as lead sponsor.

NCT NCT07328581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07328581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Open-Label, Single-Arm Study With an Initial Safety Run-In and Dose Expansion of ICG318 (BCMA-CD19-IL-15/IL15sushi cCAR T) in Participants With Refractory Systemic Lupus Erythematosus, With or Without Lupus Nephritis
Lead sponsor
iCell Gene Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
September 30, 2026
Completion date
December 31, 2028
Enrollment
20 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lupus nephritis (ln), systemic lupus erythematosus (sle)